The onset of clinically relevant action for Dymista ® 125 / 50 occurs within 30 minutes after first application of the combination
… aaah, Spring.
Do sneezy days and sleepless nights sound familiar? For people living with allergic rhinitis( AR), springtime is no walk in the park. But it doesn’ t have to be this way.
Put the spring back in your patients this spring with Dymista ® 125 / 50( azelastine hydrochloride / fluticasone propionate).
Dymista ® delivers twice the relief of AR symptoms compared with an INCS * 1, 2
* Compared to fluticasone propionate( p = 0.0013) at day 14. Reflective total 7 symptoms score( rT7SS), post-hoc analysis, placebo subtracted results( n = 610)
Rapid relief within 30 minutes † 3,4
†
The onset of clinically relevant action for Dymista ® 125 / 50 occurs within 30 minutes after first application of the combination
PBS Information: This product is not listed on the PBS.
Before prescribing Dymista ® please review the PBS and Product Information in the primary advertisement of this publication.
References: 1. Hampel FC et al. Ann Allergy Asthma Immunol 2010; 105:168-173. 2. Meltzer E et al. Int Arch Allergy Immunol 2013; 161:369-377. 3. DYMISTA ® 125 / 50 Nasal Spray Product Information. 4. Carr W et al. J Allergy Clin Immunol 2012; 129:1282-1289.
INCS: intranasal corticosteroid
Dymista ® is a registered trademark. MEDA Pharmaceuticals( Aust) Pty Ltd.( A Mylan Company). Level 1, 30 – 34 Hickson Rd, Millers Point, NSW, 2000, Australia. ABN: 29 601 608 771. Call: 1800 314 527. BB MYL2110B. DYM-2017-0246. Date of preparation: August 2017.